Introduction
============

Arterial stiffness affects the homeostasis of a living body, in which the vasodilation effect of nitric oxide (NO) plays a vital role. The salutary effects of nitroglycerin (NTG) in patients with angina pectoris are thought to be the result of the widespread action of the drug as a smooth muscle vasodilator.[@b1-vhrm-12-313] This vasodilation effect operates in the coronary artery and in systemic veins to induce pooling. It has been suggested that NTG may increase distensibility of peripheral muscular arteries and reduce systemic resistance; this action would explain the manner by which NTG reduces myocardial oxygen need and relieves the symptoms.[@b1-vhrm-12-313]--[@b4-vhrm-12-313] However, the effects of NTG on the arterial stiffness of the arteries from the origin of the aorta to the ankle have not been quantitatively evaluated. As a method for quantitative assessment of arterial stiffness, pulse wave velocity (PWV) has been used for the last several decades and it was thought to be a kind of surrogate marker of arteriosclerosis;[@b5-vhrm-12-313]--[@b9-vhrm-12-313] however, PWV depends inherently on blood pressure (BP) changes at the time of measurement.[@b10-vhrm-12-313] Therefore, there had been difficulties in interpreting the data dealing with various therapies or conditions associated with BP changes.[@b11-vhrm-12-313]--[@b16-vhrm-12-313]

In 2006, the cardio-ankle vascular index (CAVI) was developed as an arterial stiffness index, which was derived from the stiffness parameter beta theory with the application of the Bramwell--Hill equation.[@b5-vhrm-12-313],[@b6-vhrm-12-313],[@b17-vhrm-12-313] It is essentially independent from BP at the time of measurement.[@b18-vhrm-12-313],[@b19-vhrm-12-313] CAVI increases with aging,[@b20-vhrm-12-313] and it is enhanced in arteriosclerotic patients with coronary artery disease (CAD),[@b21-vhrm-12-313]--[@b23-vhrm-12-313] cerebral infarction,[@b24-vhrm-12-313],[@b25-vhrm-12-313] and chronic kidney diseases.[@b26-vhrm-12-313] CAVI is also enhanced in patients with coronary risk factors such as hypertension, diabetes mellitus, smoking, and sleep apnea syndrome; it can be decreased by the treatment of these risks.[@b27-vhrm-12-313]--[@b35-vhrm-12-313] Thus, CAVI has become established as a marker of arteriosclerosis. The stiffness shown by CAVI is thought to comprise organic stiffness and functional stiffness.[@b36-vhrm-12-313] Organic stiffness is mainly concerned with collagen, elastin, and hyaluronic acid, whereas functional stiffness is mainly smooth muscle cell contraction.[@b37-vhrm-12-313] Functional stiffness has been demonstrated using the α1-adrenoceptor blocker doxazosin, which dilates peripheral arteries and decreases BP. When doxazosin was administered to men, BP as well as CAVI decreased, indicating that CAVI was reflecting the degree of smooth muscle contraction of the arteries.[@b19-vhrm-12-313] Chiba et al reported that NTG decreased CAVI in rabbits.[@b38-vhrm-12-313] They inserted a catheter in healthy rabbits' arteries directly and developed the system that measured CAVI every 1 minute. Intravenous infusion of NTG significantly decreased CAVI, which returned to the predrug control values immediately after stopping the infusion.

The purpose of this study was to clarify the difference between effects of NTG on the functional stiffness in patients with and without CAD using the newly developed stiffness index CAVI.

Methods
=======

Subjects
--------

The normal controls were 31 healthy volunteers (males 21; females 10) aged 24--50 years (mean ± standard deviation \[SD\], 31.1±1.3 years), who came to our institute responding to our public announcement. They had no medical history and were not on regular medications. The CAD subjects were 25 patients (males 20; females 5) aged 60--84 years (mean ± SD, 73.0±5.9 years). The CAD patients comprised 19 with angina pectoris and six with old myocardial infarction; 17 patients underwent percutaneous coronary intervention, and eight patients had coronary artery bypass grafting. Blood sampling was performed after fasting for 12 hours. The details of baseline clinical characteristics are shown in [Table 1](#t1-vhrm-12-313){ref-type="table"}.

Each participant gave written informed consent after receiving a detailed description of the procedures in accordance with the Declaration of Helsinki; the study was reviewed and approved by the Ethics Committee of Toho University.

Experimental methods and design
-------------------------------

The CAD patients continued taking their daily medications during the course of the study. The study was conducted in a quiet and temperature-controlled room (25°C--26°C). The subjects were studied at approximately the same time of day after a standardized light meal and were asked to avoid caffeine or tobacco on the day of the study. After resting for 10 minutes in supine position on a bed, CAVI was measured at baseline. Next, a tablet of NTG (0.3 mg) was administered sublingually and CAVI was measured every 5 minutes for 20 minutes using a Vasela 1500 (Fukuda Denshi Co., Ltd, Tokyo, Japan). Simultaneously, BP and heart rate (HR) were measured using Vasela 1500.

Statistical analysis
--------------------

Data were expressed as mean ± SD. Comparisons of each parameter before and after taking NTG were evaluated for statistical significance by analysis of variance and post hoc tests. Tukey--Kramer test was used for post hoc comparisons. To analyze the difference between the two groups, Student's unpaired *t*-test was used. *P*-value \<0.05 was considered sig nificant. All statistical analysis was double-sided. Statistical analysis was performed using SPSS software package (SPSS Inc., Chicago, IL, USA).

Results
=======

The clinical background of the normal controls and CAD patients is listed in [Table 1](#t1-vhrm-12-313){ref-type="table"}. Age, body mass index, systolic BP, diastolic BP, and CAVI were significantly higher in the CAD patients than in the normal controls (*P*\<0.001). In addition, the CAD patients had higher glycated hemoglobin and triglyceride concentration, and lower high-density lipoprotein cholesterol level (*P*\<0.001). In these patients, 88% received treatment with statins; thus, low-density lipoprotein cholesterol level was not significantly different between the two groups. Creatinine was significantly higher in the CAD patients (*P*\<0.05). The CAD patients underwent polysomnography for sleep apnea syndrome screening as risk assessment; 48% had sleep apnea syndrome with apnea hypopnea index ≥20, and 44% were receiving treatment with continuous positive airway pressure.

The changes in CAVI, HR, and systolic/diastolic BP in the normal controls due to the administration NTG 0.3 mg are shown in [Figure 1](#f1-vhrm-12-313){ref-type="fig"}. CAVI significantly decreased from baseline after 5, 10, and 15 minutes (from 6.5±0.9 to 5.2±0.9, 5.5±0.9, and 5.7±0.9, respectively). Systolic BP and HR were not significantly changed. Diastolic BP significantly decreased from baseline after 5 and 10 minutes (from 72±8 to 64±9 and 63±9 mmHg, respectively).

The changes in each parameter in the CAD patients due to the administration of NTG 0.3 mg are shown in [Figure 2](#f2-vhrm-12-313){ref-type="fig"}. CAVI, HR, and diastolic BP were not changed significantly. Systolic BP was significantly decreased from baseline after 5, 10, and 15 minutes (from 147±16 to 131±14, 129±12, and 129±13 mmHg, respectively).

The comparison of the difference (Δ) in each parameter between the two groups is shown in [Figure 3](#f3-vhrm-12-313){ref-type="fig"}. In the comparison of the two groups, ΔCAVI was not significantly different between the normal controls and CAD patients (−1.4±0.7 vs −1.4±0.9, −1.1±0.7 vs −1.4±1.0, −0.8±0.7 vs −1.2±1.0, and −0.5±0.7 vs −1.1±1.0 at 5, 10, 15, and 20 minutes, respectively). ΔHR was not significantly different between the two groups. ΔSystolic BP in the CAD patients was significantly higher than in the normal controls at 5, 10, 15, and 20 minutes (normal controls vs CAD; −3±7 vs −10±11, −3±5 vs −10±11, −3±6 vs −13±10, and −1±6 vs −11±10, respectively). ΔDiastolic BP in the normal controls was significantly higher than in the normal controls at 5 and 10 minutes (normal controls vs CAD: −8±6 vs −4±4 and −9±4 vs −6±5, respectively).

Discussion
==========

To date, several reports have discussed the effect of NTG on arterial stiffness using PWV.[@b39-vhrm-12-313],[@b40-vhrm-12-313] However, as shown in the current study, BP decreased after NTG administration. Thus, even when PWV decreased, it cannot be concluded that NTG actually decreased arterial stiffness because PWV decreases when BP decreases.[@b19-vhrm-12-313] On the other hand, CAVI is independent of BP at the time of measurement.[@b18-vhrm-12-313],[@b19-vhrm-12-313] Taken together, the effects of the drugs that affect BP on proper arterial stiffness can be evaluated using CAVI. In this study, CAVI decreased in both the healthy young adults and CAD patients after NTG administration as shown in [Figure 1](#f1-vhrm-12-313){ref-type="fig"} and [2](#f2-vhrm-12-313){ref-type="fig"}, indicating that NTG decreased proper arterial stiffness of the artery from the origin of the aorta to the ankle. This is the first report to demonstrate the effect of NTG on proper arterial stiffness of the artery in vivo.

As to the mechanism of NTG, several hypotheses have been raised in the last 30 years. Generally, NTG dilates the coronary artery[@b4-vhrm-12-313] and increases coronary blood flow.[@b41-vhrm-12-313] However, Ogilvie reported that NTG has been demonstrated to possess unique vascular actions that dilate systemic venous vessels more potently than arterial vessels, leading to a reduction in cardiac output caused by the decreased venous return.[@b42-vhrm-12-313] The decreased CAVI in our study might indicate that NTG dilated the arterial tree composing the aorta, the so-called elastic artery, and the femoral and tibial arteries, the so-called muscular arteries. This dilation might facilitate decreasing afterload to the heart. Thus, NTG might decrease both the preload and afterload to the heart, and also relieve the stress to the heart muscles. It is also suggested that CAVI may be a useful index to at least partially express the afterload. This leads to the question of which artery might best respond to NTG, the aorta as an elastic artery or the femoral and tibial arteries as muscular arteries. Further precise studies are now under investigation.

In the comparison between the healthy volunteers and CAD patients, after NTG administration, ΔCAVI was not significantly different between the two groups.

Previously, there were some reports showing that vasodilator response to NO is maintained in CAD patients. Testa et al reported that vascular responses to NTG in patients with abnormal and normal findings on coronary angiograms were similar using blood flow velocity in the superficial femoral artery.[@b43-vhrm-12-313] Thanyasiri et al reported as to whether femoral vascular reactivity and/or fibrinolytic capacity are impaired in acute coronary syndrome patients over and above any dysfunction associated with stable CAD.[@b44-vhrm-12-313] They found that there was a significant impairment in large arterial endothelium-dependent dilatation in response to acetylcholine in both stable and acute coronary syndrome patients compared with control patients, whereas there was no significant difference in the response to NTG between the groups. These results indicate that NTG administration decreased the stiffness of the arteries from the origin of the aorta to the ankle in both the healthy volunteers and CAD patients to the same extent, which means that the response of arterial smooth muscle cells to NO was preserved even in CAD patients.

As shown in [Figure 3](#f3-vhrm-12-313){ref-type="fig"}, the decrease in systolic BP after the administration of NTG in the CAD patients was higher than that in the normal control group, while the decrease in diastolic BP in CAD patients was smaller than that in the normal control group. Arterial stiffness has a close relationship with diastolic BP. Moreover, arterial wall stiffness is a major determinant of left ventricular afterload.[@b45-vhrm-12-313] In CAD patients, arteriosclerotic states become worse with atherosclerotic changes compared to healthy volunteers. Diastolic BP might be difficult to decrease after the administration of NTG.

During the progression of arteriosclerosis, one of the major vascular qualitative changes is the calcification of arteries. Smooth muscle cells are even present in an advanced arteriosclerotic artery. Those smooth muscle cells wererelaxed or became contractual functionally. It is difficult to distinguish this organic state and functional state strictly. But, we might be able to guess the organic stiffness as the baseline of CAVI, and functional stiffness as the rapid changed CAVI by NTG.

Study limitations
=================

The CAD patients were examined under the controlled state of their various coronary risk factors. The fact that we cannot remove the effects of their medications is the limitation of our study.

Conclusion
==========

After NTG administration, the stiffness of the arteries from the origin of the aorta to the ankle as measured by CAVI decreased in both the healthy volunteers and CAD patients at nearly the same extent, suggesting that the response of the arterial smooth muscle cells to NO is preserved even in CAD patients under medications.
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![Changes in CAVI, HR, and BP after sublingual administration of nitroglycerin in normal controls (n=31).\
**Notes:** CAVI was measured using Vasela 1500 at baseline, 5, 10, 15, and 20 minutes after the administration of nitroglycerin 0.3 mg, and the value on the right side of CAVI was used. Data are presented as mean ± standard deviation; \*\**P*\<0.01, and \*\*\**P*\<0.001 (Tukey--Kramer test was used for post hoc comparisons.)\
**Abbreviations:** BP, blood pressure; CAVI, cardio-ankle vascular index, HR, heart rate.](vhrm-12-313Fig1){#f1-vhrm-12-313}

![Changes in CAVI, HR, and BP after sublingual administration of nitroglycerin 0.3 mg in CAD patents (n=25).\
**Notes:** Data are presented as mean ± standard deviation; \*\*\**P*\<0.001 (Tukey--Kramer test was used for post hoc comparisons).\
**Abbreviations:** BP, blood pressure; CAD, coronary artery disease; CAVI, cardio- ankle vascular index; HR, heart rate.](vhrm-12-313Fig2){#f2-vhrm-12-313}

![Comparison of ΔCAVI, Δheart rate, and Δblood pressure between normal controls and CAD patients during NTG administration.\
**Notes:** \*\**P*\<0.01, and \*\*\**P*\<0.001 (Tukey--Kramer test was used for post hoc comparisons); ^\#^*P*\<0.05 and ^\#\#^*P*\<0.01 (unpaired Student's *t*-test was used to compare the two groups at each time). Data are presented as mean ± SD.\
**Abbreviations:** CAD, coronary artery disease; CAVI, cardio-ankle vascular index; DBP, diastolic blood pressure; NTG, nitroglycerin; SBP, systolic blood pressure; SD, standard deviation.](vhrm-12-313Fig3){#f3-vhrm-12-313}

###### 

Characteristics of the subjects

                              Normal controls (n=31)   CAD patients (n=25)   *P*-value
  --------------------------- ------------------------ --------------------- -----------
  Sex (male/female)           21/10                    20/5                  NS
  Age (years)                 31.1±1.3                 73.0±5.9              \<0.001
  Height (cm)                 166.9±1.7                163.3±7.2             NS
  Body weight (kg)            61.8±1.7                 67.1±10.0             \<0.05
  Body mass index (kg/m^2^)   22.1±0.3                 25.1±2.4              \<0.001
  SBP (mmHg)                  117±11                   142±20                \<0.001
  DBP (mmHg)                  72±8                     85±12                 \<0.001
  Heart rate (beats/min)      65±9                     71±16                 NS
  CAVI                        6.5±0.9                  10.3±1.0              \<0.001
  HbA1c (%)                   4.8±0.2                  6.6±1.1               P\<0.001
  HDL cholesterol (mg/dL)     66±12                    50±15                 \<0.001
  LDL cholesterol (mg/dL)     92±25                    89±21                 NS
  Triglycerides (mg/dL)       75±31                    142±39                \<0.001
  Creatinine (mg/dL)          0.76±0.13                1.00±0.37             \<0.01
  Uric Acid (mg/dL)           5.9±1.5                  5.4±1.8               NS
  **Medical history**                                                        
   Hypertension               0 (0)                    25 (100)              \<0.001
   Dyslipidemia               0 (0)                    23 (92)               \<0.001
   Diabetes mellitus          0 (0)                    10 (40)               \<0.001
   Sleep apnea syndrome       0 (0)                    12 (48)               \<0.001
   Previous history of CAD    0 (0)                    25 (100)              \<0.001
   PCI/CABG                   0/0                      17/8                  \<0.001
   Smoking (none/current)     24/7                     24/1                  \<0.001
  **Medications at entry**                                                   
   Calcium antagonist         0                        14 (56)               
   ARBs                       0                        14 (56)               
   α-Blockers                 0                        0 (0)                 
   β-Blockers                 0                        6 (24)                
   Diuretics                  0                        7 (28)                
   Statins                    0                        22 (88)               
   Insulin                    0                        2 (8)                 
   Hypoglycemic agents        0                        10 (40)               
   Nitrates                   0                        8 (32)                
   CPAP                       0                        11 (44)               

**Notes:** The numbers in parentheses represent percentages. Data are presented as mean ± SD. Unpaired Student's *t*-test was used to compare the two groups.

**Abbreviations:** ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CAVI, cardio-ankle vascular index; CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SD, standard deviation.
